Vir Biotechnology, Inc.

Vir Biotechnology, Inc.

VIRNYSE / NASDAQHealthcareSmall cap

$8.39-$0.48 (-5.4%)

Last close · Data as of Nov 20, 2026

Market cap
$1.5B
Revenue
$66.5M
Net margin
-658.4%
ROCE
-62.7%

+50.9% over the last year

Vir Biotechnology, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-21.9%
3M
-8.9%
6M
-5.5%
1Y
+50.9%
5Y
-74.4%

52-week range

Day change -$0.48 (-5.4%) from $8.87 to $8.39 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in VIR, bought on each weekday since 2021.

News & filings

What Vir Biotechnology filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 438 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 4.4% in fiscal 2025 after falling 65.2% a year over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.

Read moreShow less

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Sector
Healthcare
Shares outstanding
139.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.5B
P/B
2.0x
EV / Sales
17.6x
P/S
23.2x
52-week high
$13.65
52-week low
$5.56

Profitability

Operating margin
-720.9%
Net margin
-658.4%
EBITDA margin
-703.3%
ROE
-57.2%
ROCE
-62.7%
ROA
-43.7%
Asset turnover
0.07

Growth

Revenue
$66.5M
Revenue growth, 1Y
4.4%
Revenue CAGR, 3Y
-65.2%
Net profit growth, 1Y
-16.1%
Free cash flow
-$396.6M

Solvency

Current ratio
5.54
Debt / Equity
0.13
Debt / Assets
0.10
CFO / Net profit
0.89
Cash / Market cap
30.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$66.5M
Cost of revenue$30.0k
Gross profit$66.5M
Operating expenses$546.0M
Research and development$456.0M
Selling, general and administrative$92.1M
Operating income-$479.5M
Interest and other$41.7M
Pretax income-$437.8M
Tax and other$220.0k
Net income-$438.0M

Revenue and net profit

Revenue grew 4.4% in FY2025; net profit is the dashed line.

Vir Biotechnology, Inc. revenue and net profit by fiscal year
Vir Biotechnology, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.6B$515.8M
FY2023$39.5M-$615.1M
FY2024$63.7M-$522.0M
FY2025$66.5M-$438.0M

Cash flows

FY2025: -$391.8M from operations, -$396.6M free after investment (dashed).

Vir Biotechnology, Inc. operating and free cash flow by fiscal year
Vir Biotechnology, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.7B$1.6B
FY2023-$778.8M-$800.4M
FY2024-$446.4M-$453.7M
FY2025-$391.8M-$396.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$66.5M+4.4%1Y
EBITDA
-$467.8M
Net profit
-$438.0M
Cash from operations
-$391.8M
Free cash flow
-$396.6M
Revenue CAGR, 3Y
-65.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$66.5M-$467.8M-$438.0M-$396.6M-57.2%+4.4%-16.1%

Monthly returns

Month-by-month returns of VIR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.0B
Liabilities$237.6M
Equity$765.3M
Paid-in capital$2.0B
Retained earnings-$1.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; VIR highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Vir Biotechnology, Inc. (this company)17.6x

Not shown (no positive earnings and no EV / Sales): Amylyx Pharmaceuticals, Inc., ArriVent BioPharma, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Vir Biotechnology, Inc.VIRthis company$1.5B—2.0x-57.2%—
Syndax Pharmaceuticals, Inc.SNDX$1.6B-5.6x24.7x-441.6%-7.2x
Amylyx Pharmaceuticals, Inc.AMLX$1.6B-11.0x5.2x-47.4%-9.0x
agilon health, inc.AGL$1.6B—12.5x-308.8%—
Nurix Therapeutics, Inc.NRIX$1.6B—2.9x-49.1%—
Sonida Senior Living, Inc.SNDA$1.6B-22.2x-142770.5x643445.5%96.8x
ArriVent BioPharma, Inc.AVBP$1.5B—5.0x-54.1%—
PROCEPT BioRobotics CorporationPRCT$1.5B-16.1x4.2x-26.1%-15.6x
AnaptysBio, Inc.ANAB$1.5B—40.4x-35.6%17.4x
Peer median—-13.5x5.1x-48.3%-7.2x

Year-to-date ROI

VIR since 1 January, against earlier years.

Historical volatility

VIR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Vir Biotechnology, Inc. operating margin by fiscal year
Vir Biotechnology, Inc. operating margin by fiscal year
DateOperating margin
FY202252.7%
FY2023-1698.5%
FY2024-866.7%
FY2025-720.9%
LineFY2025
Cost of revenueCost Of Revenue$30.0k
Gross profitGross Profit$66.5M
Operating expensesOperating Expense$546.0M
Research and developmentResearch And Development$456.0M
Selling, general and administrativeSelling General And Administration$92.1M
Other operating expensesOther Operating Expenses-$2.0M
Total expensesTotal Expenses$546.0M
Pretax incomePretax Income-$437.8M

Learn while you research

Academy chapters picked for Vir Biotechnology, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →